New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
11:23 EDTBIIBRoyalty Pharma acquires additional interest in TECFIDERA for $510M
Royalty Pharma announced earlier that it has acquired an additional interest in the earn-out payable to the former shareholders of Fumapharm AG for $510M in cash. The Fumapharm earn-out primarily represents an indirect interest in sales of Biogen Idec's TECFIDERA, an oral therapeutic for the treatment of relapsing-forms of multiple sclerosis. The earn-out also includes an indirect interest in sales of FUMADERM, a therapeutic approved in Germany for the treatment of moderate to severe plaque psoriasis.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 13, 2014
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
November 12, 2014
08:13 EDTBIIBBoston Biotech to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use